GLP-1 physiology informs the pharmacotherapy of obesity

GLP-1 physiology informs the pharmacotherapy of obesity

Background: Glucagon-like peptide-1 receptor agonists (GLP1RA) augment glucose-dependent insulin release and reduce glucagon secretion and gastric emptying, enabling their successful development for the treatment of type 2 diabetes (T2D). These agents also inhibit food intake and reduce body weight,...

Full description

Bibliographic Details
Main Author: Daniel J. Drucker
Format: Article
Language:English
Published: Elsevier 2022-03-01
Series:Molecular Metabolism
Subjects:
Weight loss
Hunger
Diabetes
Obesity
Brain
G protein-coupled receptor
Online Access:http://www.sciencedirect.com/science/article/pii/S2212877821001988

Internet

http://www.sciencedirect.com/science/article/pii/S2212877821001988

Similar Items